Hepatitis delta infection among persons living with HIV in Europe
- PMID: 36625770
- DOI: 10.1111/liv.15519
Hepatitis delta infection among persons living with HIV in Europe
Abstract
Background and aims: A high prevalence of hepatitis delta virus (HDV) infection, the most severe form of viral hepatitis, has been reported among persons living with HIV (PLWH) in Europe. We analysed data from a large HIV cohort collaboration to characterize HDV epidemiological trends across Europe, as well as its impact on clinical outcomes.
Methods: All PLWH with a positive hepatitis B surface antigen (HBsAg) in the Swiss HIV Cohort Study and EuroSIDA between 1988 and 2019 were tested for anti-HDV antibodies and, if positive, for HDV RNA. Demographic and clinical characteristics at initiation of antiretroviral therapy were compared between HDV-positive and HDV-negative individuals using descriptive statistics. The associations between HDV infection and overall mortality, liver-related mortality as well as hepatocellular carcinoma (HCC) were assessed using cumulative incidence plots and cause-specific multivariable Cox regression.
Results: Of 2793 HBsAg-positive participants, 1556 (56%) had stored serum available and were included. The prevalence of HDV coinfection was 15.2% (237/1556, 95% confidence interval [CI]: 13.5%-17.1%) and 66% (132/200) of HDV-positive individuals had active HDV replication. Among persons who inject drugs (PWID), the prevalence of HDV coinfection was 50.5% (182/360, 95% CI: 45.3%-55.7%), with similar estimates across Europe, compared to 4.7% (52/1109, 95% CI: 3.5%-5.9%) among other participants. During a median follow-up of 10.8 years (interquartile range 5.6-17.8), 82 (34.6%) HDV-positive and 265 (20.1%) HDV-negative individuals died. 41.5% (34/82) of deaths were liver-related in HDV-positive individuals compared to 17.7% (47/265) in HDV-negative individuals. HDV infection was associated with overall mortality (adjusted hazard ratio 1.6; 95% CI 1.2-2.1), liver-related death (2.9, 1.6-5.0) and HCC (6.3, 2.5-16.0).
Conclusion: We found a very high prevalence of hepatitis delta among PWID across Europe. Among PLWH who do not inject drugs, the prevalence was similar to that reported from populations without HIV. HDV coinfection was associated with liver-related mortality and HCC incidence.
Keywords: HCC; HIV; Hepatitis Delta; PLWH; prevalence.
© 2023 The Authors. Liver International published by John Wiley & Sons Ltd.
Similar articles
-
Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort.Liver Int. 2024 Feb;44(2):603-613. doi: 10.1111/liv.15804. Epub 2023 Dec 15. Liver Int. 2024. PMID: 38100128
-
Hepatitis delta-associated mortality in HIV/HBV-coinfected patients.J Hepatol. 2017 Feb;66(2):297-303. doi: 10.1016/j.jhep.2016.10.007. Epub 2016 Oct 14. J Hepatol. 2017. PMID: 27746337
-
The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis.J Hepatol. 2020 Sep;73(3):523-532. doi: 10.1016/j.jhep.2020.04.008. Epub 2020 Apr 23. J Hepatol. 2020. PMID: 32335166 Free PMC article.
-
Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study.J Hepatol. 2013 Nov;59(5):949-56. doi: 10.1016/j.jhep.2013.07.005. Epub 2013 Jul 10. J Hepatol. 2013. PMID: 23850875
-
New epidemiology of hepatitis delta.Liver Int. 2020 Feb;40 Suppl 1:48-53. doi: 10.1111/liv.14357. Liver Int. 2020. PMID: 32077599 Review.
Cited by
-
Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus.Lancet Oncol. 2025 Jun 26:S1470-2045(25)00403-6. doi: 10.1016/S1470-2045(25)00403-6. Online ahead of print. Lancet Oncol. 2025. PMID: 40587985 No abstract available.
-
Prevalence of Hepatitis D in People Living with HIV: A National Cross-Sectional Pilot Study.Viruses. 2024 Jun 28;16(7):1044. doi: 10.3390/v16071044. Viruses. 2024. PMID: 39066206 Free PMC article.
-
Hepatitis Delta and Liver Disease Among People Living With Hepatitis B With or Without HIV Co-Infection in Senegal.Liver Int. 2025 Mar;45(3):e70026. doi: 10.1111/liv.70026. Liver Int. 2025. PMID: 39967446 Free PMC article.
References
REFERENCES
-
- Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73(3):523-532.
-
- Chen HY, Shen DT, Ji DZ, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2019;68(3):512-521.
-
- Kushner T, Serper M, Kaplan DE. Delta hepatitis within the veterans affairs medical system in the United States: prevalence, risk factors, and outcomes. J Hepatol. 2015;63(3):586-592.
-
- Le Gal F, Brichler S, Sahli R, Chevret S, Gordien E. First international external quality assessment for hepatitis delta virus RNA quantification in plasma. Hepatology. 2016;64(5):1483-1494.
-
- Koh C, Heller T, Glenn JS. Pathogenesis of and new therapies for hepatitis D. Gastroenterology. 2019;156(2):461-76 e1.